Comparative Study of Blood Loss in Total Laparoscopic Hysterectomy by Ligation the Uterine Arteries in Different Techniques.
May 1, 2026 updated by: Mostafa Bahaa
Following Caesarean section, hysterectomy is the second most common major gynecological surgery, with approximately 600,000 procedures performed annually in the USA.
Since Reich et al. first reported a total laparoscopic hysterectomy (TLH) in 1989, numerous studies have confirmed its feasibility and reproducibility.
Evidence increasingly supports TLH over vaginal hysterectomy (VH) and total abdominal hysterectomy (TAH) for benign gynecological conditions.
The development and rapid advancement of laparoscopic instruments and techniques have enabled the safe and successful completion of complex procedures using minimally invasive approaches.
Women with a higher BMI or requiring complex surgeries benefit from reduced postoperative complications with laparoscopic operations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Damietta
-
Damietta, New Damietta, Egypt, 34518
- Mostafa Bahaa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged between 35-60 years Patients presented with menometrorrhagia unresponsive to medical treatment, and uterine pathology such as adenomyosis or multiple fibroids.
Exclusion Criteria:
- Patients were excluded if they had: medical conditions preventing pneumo-peritoneum
- Patients with medical conditions hindering proper ventilation during general anesthesia.
- Patients diagnosed with endometrial carcinoma and patients with uterine size larger than 24 weeks were excluded.
- Patients with excessive adhesions precluding access to the uterine arteries were not enrolled in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control group
Group 1 (BTLH with bilateral uterine artery ligation from its origin): The round ligament close to the pelvic side wall is first coagulated and separated before the procedure is applied.
|
The round ligament close to the pelvic side wall is first coagulated and separated before the procedure is applied.
Further incision is then made in the peritoneum.
The bladder fold is pulled downward by opening the anterior leaf of the wide ligament.
It shows the ureters lateralized and the posterior leaf of the wide ligament.
After that, the ureters' path is shown, the retroperitoneal area is revealed, and the location where the uterine artery leaves the iliac artery is seen.
|
|
Active Comparator: Conventional TLH
The conventional TLH technique involved division of the corneal pedicles and securing the uterine pedicles.
Preoperative Preparation of bowel wasn't routinely done to improve enhanced recovery of patients.
|
The conventional TLH technique involved division of the corneal pedicles and securing the uterine pedicles.
Preoperative Preparation of bowel wasn't routinely done to improve enhanced recovery of patients.
Antibiotic prophylaxis with 3rd generation cephalosporin and metronidazole was given one hour preoperatively.
Obese patients received subcutaneous low molecular weight heparin and compression devices after surgery.
Under general anesthesia, patients were placed in a Lloyd Davis position.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra operative blood loss
Time Frame: 24 hours
|
Vaginal vault is identified and cut laparoscopically using monopolar hook over the manipulator cup and bipolar grasper for hemostasis until the specimen is detached completely. The uterus with cervix is delivered vaginally. The vaginal vault is sutured laparoscopically with number 1 delayed absorbable suture (Polyglactin; vicryl). The total blood loss is calculated from the suction apparatus. |
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 12, 2025
Primary Completion (Actual)
June 20, 2025
Study Completion (Actual)
June 20, 2025
Study Registration Dates
First Submitted
March 9, 2025
First Submitted That Met QC Criteria
March 9, 2025
First Posted (Actual)
March 13, 2025
Study Record Updates
Last Update Posted (Actual)
May 4, 2026
Last Update Submitted That Met QC Criteria
May 1, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8749
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.